Jardiance Geriatric (65+) Developmental Impact: What Clinicians and Patients Need to Know

Why Age Changes the Empagliflozin Risk-Benefit Equation

Empagliflozin works the same way at 70 as it does at 45. The SGLT2 transporter in the proximal tubule is inhibited, glucose is excreted in urine, and modest osmotic diuresis follows. What changes with age is the physiological context around that mechanism.

Older kidneys lose roughly 1 mL/min/1.73 m2 of GFR per year after age 40, so a 72-year-old with a serum creatinine that looks "normal" may already have an eGFR in the 50s. The FDA label for empagliflozin notes no pharmacokinetic dose adjustment is required on the basis of age alone, but it explicitly ties glycemic initiation to an eGFR threshold of at least 30 mL/min/1.73 m2.

Cardiac and vascular aging compounds this. Older adults have stiffer vessels, reduced baroreflex sensitivity, and a higher prevalence of baseline orthostatic hypotension. Osmotic diuresis that a 50-year-old tolerates without incident may precipitate symptomatic hypotension or acute kidney injury in a frail 78-year-old already on a loop diuretic and an ACE inhibitor.

The Frailty Dimension

Frailty is not synonymous with age, but its prevalence rises sharply after 75. A 2019 analysis published in JAMA Internal Medicine found that frail older adults are systematically underrepresented in cardiovascular outcome trials, including the trials that established SGLT2 inhibitor benefits. This matters because the EMPA-REG OUTCOME trial enrolled patients with a mean age of 63, and its 65+ subgroup, while prespecified, was not stratified by frailty status.

Clinicians should assess frailty using a validated instrument, such as the Clinical Frailty Scale or the Fried phenotype criteria, before starting empagliflozin in adults older than 75. A patient scoring 5 or higher on the Clinical Frailty Scale warrants a lower threshold for dose reduction or discontinuation at the first sign of volume depletion.

Polypharmacy and Drug Interactions

The average Medicare beneficiary takes 4.5 prescription medications. Empagliflozin's additive diuretic effect can tip the balance when layered onto existing thiazides, loop diuretics, or mineralocorticoid antagonists. The FDA prescribing information recommends monitoring for volume depletion symptoms when combining empagliflozin with these agents, and clinicians may need to reduce diuretic doses before initiating the SGLT2 inhibitor.

Insulin and sulfonylureas co-prescribed with empagliflozin raise hypoglycemia risk. In older adults, hypoglycemia carries a steeper penalty: a 2021 systematic review in The BMJ linked recurrent hypoglycemic episodes to accelerated cognitive decline and a higher fall rate in adults over 65.

EMPA-REG OUTCOME: What the 65+ Subgroup Actually Showed

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease and followed them for a median of 3.1 years. The primary endpoint was a three-point MACE composite. The overall trial showed a 14% relative risk reduction in MACE with empagliflozin versus placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority). Zinman et al., NEJM 2015.

The Pre-Specified Age Subgroup

The pre-specified subgroup analysis of patients aged 65 and older (approximately 2,200 participants) showed directionally consistent results for the MACE endpoint. The cardiovascular death component was numerically stronger in older patients: the absolute risk reduction for CV death was larger in the 65+ cohort than in younger participants, reflecting the higher baseline event rate in older adults with established CVD.

Hospitalization for heart failure (HHF) was cut by 35% in the overall trial (HR 0.65, 95% CI 0.50 to 0.85). This benefit was preserved in the geriatric subgroup, a finding that carries particular weight because heart failure prevalence climbs steeply with age. According to CDC surveillance data, roughly 6.7 million Americans over 40 live with heart failure, and the majority are over 65.

Renal Outcomes in Older Patients

The EMPA-REG OUTCOME secondary renal endpoint, a composite of incident macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy, or renal death, was reduced by 39% in the empagliflozin arm (HR 0.61, 95% CI 0.53 to 0.70). Wanner et al., NEJM 2016. Older adults benefit from this nephroprotective effect to the same or greater degree than younger patients, partly because CKD stage 3 or higher is far more common in this age group. The CREDENCE trial (canagliflozin, not empagliflozin, but class-level evidence) and the DAPA-CKD trial both reinforced this renal signal across age subgroups.

Cardiovascular Benefit: Mechanisms That Matter More in Older Hearts

The cardiovascular benefit of empagliflozin in older adults does not rely on glucose lowering. A 2022 review in the Journal of the American College of Cardiology outlines several cardiorenal mechanisms that operate largely independent of glycemic status: reduction in preload and afterload via osmotic diuresis, suppression of the sodium-hydrogen exchanger NHE3 in the kidney, attenuation of cardiac fibrosis, and modest ketone body upregulation that may serve as an alternative myocardial fuel.

Heart Failure With Preserved Ejection Fraction

HFpEF affects older women disproportionately, and until 2021, no therapy had shown a convincing mortality benefit in this phenotype. The EMPEROR-Preserved trial (N=5,988; mean age 72) showed empagliflozin reduced the composite of CV death or HHF by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) in patients with HFpEF or HFmrEF. Anker et al., NEJM 2021. The mean age of 72 in that trial means the findings translate directly to geriatric practice without requiring extrapolation.

Heart Failure With Reduced Ejection Fraction

The EMPEROR-Reduced trial (N=3,730) showed a 25% reduction in CV death or HHF with empagliflozin in HFrEF patients (HR 0.75, 95% CI 0.65 to 0.86, P<0.001). Packer et al., NEJM 2020. The 2024 ADA Standards of Medical Care in Diabetes state: "In patients with type 2 diabetes and established heart failure, an SGLT2 inhibitor with proven benefit is recommended to reduce the risk of worsening heart failure and cardiovascular death." ADA Standards 2024, Section 10.

Adverse Effects That Disproportionately Affect the Geriatric Patient

Volume Depletion and Acute Kidney Injury

Empagliflozin causes roughly 400 mL/day of additional urine output at steady state. In a well-hydrated 50-year-old, this is inconsequential. In a 74-year-old with reduced thirst sensation, impaired renal concentrating ability, and concurrent furosemide therapy, it can produce clinically meaningful volume depletion within the first two weeks of therapy.

The FDA pharmacovigilance database has received post-marketing reports of acute kidney injury with SGLT2 inhibitors, prompting a 2016 FDA Drug Safety Communication recommending monitoring of renal function before and after initiation. Checking eGFR and serum creatinine at 4 weeks post-initiation is reasonable in all geriatric patients, and sooner if the patient reports lightheadedness, decreased urine output, or rapid weight loss.

Genital Mycotic Infections and Urinary Tract Infections

Glycosuria creates a substrate-rich environment for fungal and bacterial growth in the genitourinary tract. In EMPA-REG OUTCOME, genital mycotic infections occurred in 6.4% of empagliflozin patients versus 1.8% in placebo. Zinman et al., NEJM 2015. Older women with atrophic vaginitis and older men with phimosis or poor hygiene access face an elevated baseline risk. Clinicians should perform a brief genitourinary review at each follow-up visit during the first six months of therapy.

UTIs occur at similar rates between drug and placebo in large trials, but individual older patients with neurogenic bladder, indwelling catheters, or recurrent UTI history warrant extra caution. Empagliflozin should be held during any active UTI until resolution.

Falls, Fractures, and Amputation

Empagliflozin did not produce a statistically significant increase in lower-limb amputations in EMPA-REG OUTCOME, in contrast to canagliflozin in the CANVAS trial. A 2019 meta-analysis in Diabetes Care found the amputation risk with empagliflozin was not elevated above placebo (RR 1.09, 95% CI 0.63 to 1.87). Fracture risk similarly did not reach significance.

Orthostatic hypotension from volume depletion can increase fall risk in older adults. A practical step: measure lying and standing blood pressure at the first follow-up visit after initiating empagliflozin in any patient over 70.

Diabetic Ketoacidosis

Euglycemic diabetic ketoacidosis (DKA) is rare but more likely during physiological stress: surgery, infection, prolonged fasting, or severe illness. Older adults experience these stressors more frequently. The FDA label advises holding empagliflozin at least 3 days before any scheduled surgery. Clinicians should provide explicit sick-day instructions, particularly for patients with limited health literacy or who live alone.

Dosing and Initiation Protocol for Geriatric Patients

The following framework is designed for clinical teams initiating empagliflozin in adults aged 65 and older. It synthesizes the FDA label, the 2024 ADA Standards, and the EMPEROR trial age subgroup data into a single workflow.

Pre-Initiation Checklist

1. Confirm eGFR is at least 30 mL/min/1.73 m2 for glycemic indication (eGFR at least 20 mL/min/1.73 m2 for HF indication per FDA labeling update 2023).
2. Review current diuretic therapy. If the patient is on a loop diuretic at more than 40 mg furosemide equivalent daily, consider a 25% dose reduction before starting empagliflozin.
3. Check sitting and standing blood pressure. Hold initiation if orthostatic drop exceeds 20 mmHg systolic or 10 mmHg diastolic.
4. Screen for recurrent UTI, active genital infection, or history of DKA.
5. Perform a brief frailty screen. A Clinical Frailty Scale score of 5 or higher should trigger shared decision-making about whether the cardiac or renal benefit outweighs the volume-depletion risk in that specific patient.

Starting Dose and Titration

Start at 10 mg once daily with or without food. Titration to 25 mg daily may be considered at 4 to 12 weeks if tolerated and additional glycemic control is needed. The FDA label does not mandate titration beyond 10 mg for cardiovascular or renal indications. Many geriatric patients achieve adequate benefit at 10 mg and do not require the higher dose.

Monitoring Schedule After Initiation

• Week 2: Phone or portal check-in for symptoms of volume depletion (dizziness, decreased urination, thirst, rapid weight loss).
• Week 4: In-person eGFR, electrolytes, blood pressure (lying and standing).
• Month 3: Full metabolic panel, A1C if glycemic indication, blood pressure.
• Every 6 months thereafter: eGFR, electrolytes, genitourinary review.

Hold empagliflozin and reassess if eGFR falls below 30 mL/min/1.73 m2 (glycemic use) or below 20 mL/min/1.73 m2 (HF use), or if the patient is hospitalized for any acute illness.

Glycemic Considerations in Older Adults With Type 2 Diabetes

Empagliflozin provides modest A1C reduction, typically 0.5% to 0.8% from baseline in clinical trials. In older adults, tight glycemic control is often not the primary goal. The 2023 American Geriatrics Society Beers Criteria advise against A1C targets below 7.5% in older adults with moderate to severe frailty, multiple comorbidities, or life expectancy under 10 years, because hypoglycemia risk outweighs any microvascular benefit in these populations.

Empagliflozin's insulin-independent mechanism of action means it carries negligible intrinsic hypoglycemia risk when used without insulin or sulfonylureas. This is a genuine advantage in geriatric prescribing. The risk emerges only when empagliflozin is combined with hypoglycemia-prone agents, and dose reductions in those agents should be made at initiation.

For older adults whose primary indication is cardiovascular risk reduction or nephroprotection rather than glycemic control, the relevant clinical threshold is eGFR adequacy, not A1C target.

Renal Protection in CKD Stages 3a to 3b: The Geriatric Sweet Spot

CKD stage 3 (eGFR 30 to 59 mL/min/1.73 m2) affects approximately 30% of adults over 65 in the United States, based on NHANES surveillance data cited by the CDC. This eGFR range is precisely where empagliflozin's nephroprotective effects are most needed and where glucose-lowering efficacy diminishes due to reduced tubular glucose delivery.

The EMPA-KIDNEY trial (N=6,609; median eGFR 37.3 mL/min/1.73 m2) confirmed this class-effect: empagliflozin reduced the risk of kidney disease progression or CV death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) in patients with CKD, many of whom had eGFRs in the stage 3 range. The trial's median age was 64, and subgroup analyses did not show attenuation of benefit in older participants.

Prescribers sometimes hesitate to start an SGLT2 inhibitor in a patient with eGFR of 35 mL/min/1.73 m2, fearing further acute decline. This hesitation is understandable but may deny benefit. The expected early eGFR dip of 2 to 5 mL/min/1.73 m2 on initiation is hemodynamic, not structural, and resolves after discontinuation. Long-term eGFR slopes are preserved or improved with continued therapy, as demonstrated in EMPA-KIDNEY.

Patient and Caregiver Education Priorities for Geriatric Initiation

Communicating the Urination Change

Older adults may interpret increased urination as a worsening problem or a medication error. Proactively explaining that mild polyuria is expected, and that it typically stabilizes within 2 to 4 weeks, prevents unnecessary early discontinuation. At the same time, patients should be told to report any decreased urination or dark urine, which may signal dehydration rather than a side effect plateau.

Sick-Day Rules

Empagliflozin should be held during any illness causing reduced oral intake, vomiting, diarrhea, or fever. Written sick-day instructions using plain language improve adherence to this guidance in older adults with lower health literacy. A brief checklist card given at prescription is more effective than verbal instruction alone, based on health literacy research summarized by the NIH.

Foot and Skin Care

Glycosuria and any residual peripheral neuropathy increase skin breakdown risk in older diabetic patients. Patients should inspect feet daily, keep the perineal area dry, and report any new skin lesion, blister, or ulcer promptly.

What ADA 2024 Guidelines Say About SGLT2 Inhibitors in Older Adults

The 2024 ADA Standards of Medical Care in Diabetes explicitly address SGLT2 inhibitor use across age groups. Section 10 states: "For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors with proven cardiovascular or kidney benefit are recommended as part of the glucose-lowering regimen independent of baseline A1C." ADA Standards 2024, Section 10.

The guidelines do not carve out an age-based exclusion. The clinical judgment required in geriatric patients is about tolerability, not about whether the drug class is appropriate for older adults as a category. Patients over 65 with established CVD, HF, or CKD stage 3 are, in fact, the population most likely to benefit from the cardiorenal effects of empagliflozin, precisely because their absolute event rates are higher.

The Endocrine Society 2020 guideline on type 2 diabetes management similarly endorses SGLT2 inhibitors with cardiovascular outcome data in patients with established CVD, and does not restrict this to age groups below 65. Endocrine Society Clinical Practice Guideline, JCEM 2020.

Special Populations Within the Geriatric Cohort

Adults Over 80

No large randomized trial has specifically enrolled adults aged 80 and older in sufficient numbers to generate subgroup-level cardiovascular outcome data for empagliflozin. The available evidence is extrapolated from the 65 to 79 age range. Prescribers should use clinical judgment, prioritize fall prevention, and set a low threshold for dose reduction or drug holiday during intercurrent illness in this age group.

Cognitively Impaired Patients

Patients with mild to moderate dementia may not reliably report symptoms of hypoglycemia, volume depletion, or genitourinary infection. Caregiver involvement in monitoring is mandatory. Structured caregiver education at initiation, covering the three key early warning signs (dizziness, decreased urination, genital itching or discharge), reduces the time to appropriate clinical contact when a problem develops.

Nursing Home Residents

Nursing home residents often have multiple clinical indications for empagliflozin (heart failure, CKD, diabetes) alongside restricted mobility and incontinence management challenges. Increased urinary frequency from SGLT2 inhibition can worsen incontinence, cause nighttime falls related to bathroom trips, and increase skin breakdown in incontinent patients. A formal incontinence assessment and a documented plan for managing increased urine output should be part of any initiation discussion in this setting.